The global hemostasis analyzers market is expected to witness significant growth over the forecast period. Rising incidences of blood clotting diagnosis for patients particularly those who are more prone to lose excess blood from body during surgeries is expected to propel the market growth for hemostasis analyzer or coagulation testing market. Hemostasis analyzers are instruments assisting the medical practitioners in treating patients with bleeding disorder or blood clotting. Continuous innovation in technology led to introduction of many novel drugs and devices such as introduction of high throughput hemostasis analyzers, is anticipated to boost the market growth over the forecast period. Furthermore, increasing demand for technological advancements for medical treatment, strong government support, and rising trend in laboratory automation market is expected to drive the global hemostasis analyzer market. Huge investment in R&D to avoid being obsolete coupled with increasing awareness among the global population provide significant growth opportunity to this market in coming few years. High rate of adoption of automated hemostasis equipment in diagnostic laboratories and growing number of campaigns in emerging economies is anticipated to create huge potential market.
The global hemostasis analyzers market is segmented on the basis of product, technology, test type and end use. By product, the market is bifurcated into clinical laboratory analyzers and hemostasis analyzers for point-of-care (POC) testing. The market is anticipated to witness lucrative growth over the forecast period owing to rising demand for automated hemostasis analyzers in medical diagnosis. Apart from automated hemostasis analyzers, the market has semi-automated and manual hemostasis analyzers. By technology, the market is classified into mechanical, electrochemical, optical and others. Mechanical hemostasis analyzers market is anticipated to witness considerable market share due to more sophisticated, accurate and efficient management at a lower cost. On the basis of test type, the market is fragmented into APTT test, D dimer test, fibrinogen test prothrombin time (PT) test and other testing markets. D dimer test includes tests in platelets free plasma, platelets rich plasma and whole body test to obtain a complete picture of patient’s hemostasis work. By end-use the market is again classified into hospitals, research institutes, diagnostic centers, and others. Due to the adoption of the latest technology and heavy budgetary expenditure the medical and research institutes is likely to witness lucrative growth over the forecast period.
In 2014, North America was the dominant region in global coagulation/hemostasis analyzers market in terms of revenue. Owing to developed healthcare infrastructure, rising R&D activities, growing incidences of surgeries & organ transplant procedures, and increasing prevalence of hemostasis disorders are factors anticipated to maintain its dominance over the forecast period. Asia Pacific region is expected to show the highest CAGR over the forecast period due to increasing awareness about hemostasis coupled with increasing number of campaigns in this region.
Key market players of the global hemostasis analyzers market are Siemens Healthcare, Thermo Fisher Scientific, Inc., Instrumentation Laboratory Werfen Group, Sysmex Corporation, Roche Diagnostics, International Technidyne Corporation, Alere Inc. and Nihon Kohden Corporation. The market is highly competitive due to the presence of large number of market players.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.